Skip to main content
Top
Published in: Current HIV/AIDS Reports 4/2018

01-08-2018 | The Global Epidemic (SH Vermund, Section Editor)

Young Drug Users: a Vulnerable Population and an Underutilized Resource in HIV/HCV Prevention

Authors: Pedro Mateu-Gelabert, H. Guarino, K. Quinn, P. Meylakhs, S. Campos, A. Meylakhs, D. Berbesi, D. Toro-Tobón, E. Goodbody, D.C. Ompad, S. R. Friedman

Published in: Current HIV/AIDS Reports | Issue 4/2018

Login to get access

Abstract

Purpose of Review

The social networks of people who inject drugs (PWID) have long been studied to understand disease transmission dynamics and social influences on risky practices. We illustrate how PWID can be active agents promoting HIV, HCV, and overdose prevention.

Recent Findings

We assessed drug users’ connections and interactions with others at risk for HIV/HCV in three cities: New York City (NYC), USA (n = 539); Pereira, Colombia (n = 50); and St. Petersburg, Russia (n = 49). In all three cities, the majority of participants’ network members were of a similar age as themselves, yet connections across age groups were also present. In NYC, knowing any opioid user(s) older than 29 was associated with testing HCV-positive. In NYC and St. Petersburg, a large proportion of PWID engaged in intravention activities to support safer injection and overdose prevention; in Pereira, PWID injected, had sex, and interacted with other key groups at risk.

Summary

People who use drugs can be active players in HIV/HCV and overdose risk- reduction; their networks provide them with ample opportunities to disseminate harm reduction knowledge, strategies, and norms to others at risk. Local communities could augment prevention programming by empowering drug users to be allies in the fight against HIV and facilitating their pre-existing health-protective actions.
Literature
1.
go back to reference Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickeran P. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5:e1192–207.CrossRefPubMedPubMedCentral Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickeran P. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5:e1192–207.CrossRefPubMedPubMedCentral
4.
go back to reference Mathers BM, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick RP. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet. 2010;375:1014–28.CrossRefPubMed Mathers BM, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick RP. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet. 2010;375:1014–28.CrossRefPubMed
5.
go back to reference Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, Hickman M. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet. 2010;376:285–301.CrossRefPubMed Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, Hickman M. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet. 2010;376:285–301.CrossRefPubMed
6.
go back to reference Des Jarlais DC, Hagan H, Friedman SR, Friedmann P, Goldberg D, Frischer M. Maintaining low HIV seroprevalence in populations of injecting drug users. JAMA. 1995;274:1226–31.CrossRefPubMed Des Jarlais DC, Hagan H, Friedman SR, Friedmann P, Goldberg D, Frischer M. Maintaining low HIV seroprevalence in populations of injecting drug users. JAMA. 1995;274:1226–31.CrossRefPubMed
7.
go back to reference Wilson DP, Donald B, Shattock AJ, Wilson D, Fraser-Hurt N. The cost-effectiveness of harm reduction. Int J Drug Policy. 2015;26:S5–S11.CrossRefPubMed Wilson DP, Donald B, Shattock AJ, Wilson D, Fraser-Hurt N. The cost-effectiveness of harm reduction. Int J Drug Policy. 2015;26:S5–S11.CrossRefPubMed
8.
go back to reference Jones CM, Christensen A, Gladden RM. Increases in prescription opioid injection abuse among treatment admissions in the United States, 2004–2013. Drug Alcohol Depend. 2017;176:89–95.CrossRefPubMed Jones CM, Christensen A, Gladden RM. Increases in prescription opioid injection abuse among treatment admissions in the United States, 2004–2013. Drug Alcohol Depend. 2017;176:89–95.CrossRefPubMed
10.
go back to reference Zibbell JE, Iqbal K, Patel RC, Suryaprasad A, Sanders KJ, Moore-Moravian. Increases in hepatitis C virus infection related to injection drug use among persons aged≤ 30 years-Kentucky, Tennessee, Virginia, and West Virginia, 2006-2012. MMWR. 2015;64:453–8.PubMed Zibbell JE, Iqbal K, Patel RC, Suryaprasad A, Sanders KJ, Moore-Moravian. Increases in hepatitis C virus infection related to injection drug use among persons aged≤ 30 years-Kentucky, Tennessee, Virginia, and West Virginia, 2006-2012. MMWR. 2015;64:453–8.PubMed
11.
go back to reference Ly KN, Hughes EM, Jiles RB, Holmberg SD. Rising mortality associated with hepatitis C virus in the United States, 2003–2013. Clin Infect Dis. 2016;62:1287–8.CrossRefPubMed Ly KN, Hughes EM, Jiles RB, Holmberg SD. Rising mortality associated with hepatitis C virus in the United States, 2003–2013. Clin Infect Dis. 2016;62:1287–8.CrossRefPubMed
12.
go back to reference Campbell CA, Canary L, Smith N, Teshale E, Blythe Ryerson A, Ward JW. State HCV incidence and policies related to HCV preventive and treatment services for persons who inject drugs—United States, 2015–2016. Am J Transplant. 2017;17(7):1945–8.CrossRefPubMed Campbell CA, Canary L, Smith N, Teshale E, Blythe Ryerson A, Ward JW. State HCV incidence and policies related to HCV preventive and treatment services for persons who inject drugs—United States, 2015–2016. Am J Transplant. 2017;17(7):1945–8.CrossRefPubMed
13.
go back to reference Curtis R, Friedman SR, Neaigus A, Jose B, Goldstein M, Ildefonso G. Street-level drug markets: network structure and HIV risk. Soc Networks. 1995;17(3–4):229–49.CrossRef Curtis R, Friedman SR, Neaigus A, Jose B, Goldstein M, Ildefonso G. Street-level drug markets: network structure and HIV risk. Soc Networks. 1995;17(3–4):229–49.CrossRef
14.
go back to reference Friedman SR, Neaigus A, Jose B, Curtis R, Goldstein M, Ildefonso G. Sociometric risk networks and risk for HIV infection. Am J Public Health. 1997;87(8):1289–96.CrossRefPubMedPubMedCentral Friedman SR, Neaigus A, Jose B, Curtis R, Goldstein M, Ildefonso G. Sociometric risk networks and risk for HIV infection. Am J Public Health. 1997;87(8):1289–96.CrossRefPubMedPubMedCentral
15.
go back to reference Klovdahl AS, Potterat JJ, Woodhouse DE, Muth JB, Muth SQ, Darrow WW. Social networks and infectious disease: the Colorado Springs study. Soc Sci Med. 1994;38(1):79–88.CrossRefPubMed Klovdahl AS, Potterat JJ, Woodhouse DE, Muth JB, Muth SQ, Darrow WW. Social networks and infectious disease: the Colorado Springs study. Soc Sci Med. 1994;38(1):79–88.CrossRefPubMed
16.
go back to reference Suh T, Mandell W, Latkin C, Kim J. Social network characteristics and injecting HIV-risk behaviors among street injection drug users. Drug Alcohol Depend. 1997;47(2):137–43.CrossRefPubMed Suh T, Mandell W, Latkin C, Kim J. Social network characteristics and injecting HIV-risk behaviors among street injection drug users. Drug Alcohol Depend. 1997;47(2):137–43.CrossRefPubMed
17.
go back to reference Weeks MR, Clair S, Borgatti SP, Radda K, Schensul JJ. Social networks of drug users in high-risk sites: finding the connections. AIDS Behav. 2002;6(2):193–206.CrossRef Weeks MR, Clair S, Borgatti SP, Radda K, Schensul JJ. Social networks of drug users in high-risk sites: finding the connections. AIDS Behav. 2002;6(2):193–206.CrossRef
18.
go back to reference Bouchard M, Hashimi S, Tsai K, Lampkin H, Jozaghi E. Back to the core: a network approach to bolster harm reduction among persons who inject drugs. Int J Drug Policy. 2018;51:95–104.CrossRefPubMed Bouchard M, Hashimi S, Tsai K, Lampkin H, Jozaghi E. Back to the core: a network approach to bolster harm reduction among persons who inject drugs. Int J Drug Policy. 2018;51:95–104.CrossRefPubMed
19.
go back to reference Latkin CA, Sherman S, Knowlton A. HIV prevention among drug users: outcome of a network-oriented peer outreach intervention. Health Psychol. 2003;22:332–9.CrossRefPubMed Latkin CA, Sherman S, Knowlton A. HIV prevention among drug users: outcome of a network-oriented peer outreach intervention. Health Psychol. 2003;22:332–9.CrossRefPubMed
20.
go back to reference Medley A, Kennedy C, O'Reilly K, Sweat M. Effectiveness of peer education interventions for HIV prevention in developing countries: a systematic review and meta-analysis. AIDS Educ Prev. 2009;21:181–206.CrossRefPubMedPubMedCentral Medley A, Kennedy C, O'Reilly K, Sweat M. Effectiveness of peer education interventions for HIV prevention in developing countries: a systematic review and meta-analysis. AIDS Educ Prev. 2009;21:181–206.CrossRefPubMedPubMedCentral
21.
go back to reference McCabe SE, Cranford JA, West BT. Trends in prescription drug abuse and dependence, co-occurrence with other substance use disorders, and treatment utilization: results from two national surveys. Addict Behav. 2008;33:1297–305.CrossRefPubMedPubMedCentral McCabe SE, Cranford JA, West BT. Trends in prescription drug abuse and dependence, co-occurrence with other substance use disorders, and treatment utilization: results from two national surveys. Addict Behav. 2008;33:1297–305.CrossRefPubMedPubMedCentral
22.
go back to reference Paulozzi LJ, Budnitz DS, Xi Y. Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Saf. 2006;15:618–27.CrossRefPubMed Paulozzi LJ, Budnitz DS, Xi Y. Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Saf. 2006;15:618–27.CrossRefPubMed
23.
go back to reference Rudd RA, Aleshire N, Zibbell JE, Matthew Gladden R. Increases in drug and opioid overdose deaths—United States, 2000–2014. Am J Transplant. 2016;16:1323–7.CrossRef Rudd RA, Aleshire N, Zibbell JE, Matthew Gladden R. Increases in drug and opioid overdose deaths—United States, 2000–2014. Am J Transplant. 2016;16:1323–7.CrossRef
24.
go back to reference Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. JAMA psychiatry. 2014;71:821–6.CrossRefPubMed Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. JAMA psychiatry. 2014;71:821–6.CrossRefPubMed
25.
go back to reference Compton WM, Jones CM, Baldwin GT. Relationship between nonmedical prescription-opioid use and heroin use. N Engl J Med. 2016;374:154–63.CrossRefPubMed Compton WM, Jones CM, Baldwin GT. Relationship between nonmedical prescription-opioid use and heroin use. N Engl J Med. 2016;374:154–63.CrossRefPubMed
26.
go back to reference Jones CM. Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers–United States, 2002–2004 and 2008–2010. Drug Alcohol Depend. 2013;132:95–100.CrossRefPubMed Jones CM. Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers–United States, 2002–2004 and 2008–2010. Drug Alcohol Depend. 2013;132:95–100.CrossRefPubMed
27.
go back to reference Tempalski B, Pouget ER, Cleland CM, Brady JE, Cooper HL, Hall HI. Trends in the population prevalence of people who inject drugs in US metropolitan areas 1992–2007. PLoS One. 2013;8:e64789.CrossRefPubMedPubMedCentral Tempalski B, Pouget ER, Cleland CM, Brady JE, Cooper HL, Hall HI. Trends in the population prevalence of people who inject drugs in US metropolitan areas 1992–2007. PLoS One. 2013;8:e64789.CrossRefPubMedPubMedCentral
28.
go back to reference Suryaprasad AG, White JZ, Xu F, Eichler BA, Hamilton J, Patel A. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006–2012. Clin Infect Dis. 2014;59:1411–9.CrossRefPubMed Suryaprasad AG, White JZ, Xu F, Eichler BA, Hamilton J, Patel A. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006–2012. Clin Infect Dis. 2014;59:1411–9.CrossRefPubMed
29.
go back to reference Friedman SR, Maslow C, Bolyard M, Sandoval M, Mateu-Gelabert P, Neaigus A. Urging others to be healthy: “Intravention” by injection drug users as a community prevention goal. AIDS Educ Prev. 2004;16:250–63.CrossRefPubMed Friedman SR, Maslow C, Bolyard M, Sandoval M, Mateu-Gelabert P, Neaigus A. Urging others to be healthy: “Intravention” by injection drug users as a community prevention goal. AIDS Educ Prev. 2004;16:250–63.CrossRefPubMed
32.
33.
go back to reference Lunze K, Raj A, Cheng DM, Quinn EK, Lunze FI, Liebschutz JM. Sexual violence from police and HIV risk behaviours among HIV-positive women who inject drugs in St. Petersburg, Russia—a mixed methods study. J Int AIDS Soc. 2016;19(4Suppl3):20877.PubMedPubMedCentral Lunze K, Raj A, Cheng DM, Quinn EK, Lunze FI, Liebschutz JM. Sexual violence from police and HIV risk behaviours among HIV-positive women who inject drugs in St. Petersburg, Russia—a mixed methods study. J Int AIDS Soc. 2016;19(4Suppl3):20877.PubMedPubMedCentral
34.
35.
go back to reference Ciccarone D. Heroin in brown, black and white: structural factors and medical consequences in the US heroin market. Int J Drug Policy. 2009;20:277–82.CrossRefPubMed Ciccarone D. Heroin in brown, black and white: structural factors and medical consequences in the US heroin market. Int J Drug Policy. 2009;20:277–82.CrossRefPubMed
37.
go back to reference Hacker MA, Malta M, Enriquez M, Bastos FI. Human immunodeficiency virus, AIDS, and drug consumption in South America and the Caribbean: epidemiological evidence and initiatives to curb the epidemic. Rev Panam Salud Publica. 2005;18:303–13.CrossRefPubMed Hacker MA, Malta M, Enriquez M, Bastos FI. Human immunodeficiency virus, AIDS, and drug consumption in South America and the Caribbean: epidemiological evidence and initiatives to curb the epidemic. Rev Panam Salud Publica. 2005;18:303–13.CrossRefPubMed
38.
go back to reference Miguez MJ, Page B, Baum MK. Illegal drug use and HIV-1 infection in Colombia. Lancet. 1997;350:1635.CrossRefPubMed Miguez MJ, Page B, Baum MK. Illegal drug use and HIV-1 infection in Colombia. Lancet. 1997;350:1635.CrossRefPubMed
39.
go back to reference Mateu-Gelabert P, Harris S, Berbesi D, Segura Cardona ÁM, Montoya Vélez LP, Mejía Motta IE. Heroin use and injection risk behaviors in Colombia: implications for HIV/AIDS prevention. Subst Use Misuse. 2016;51:230–40.CrossRefPubMedPubMedCentral Mateu-Gelabert P, Harris S, Berbesi D, Segura Cardona ÁM, Montoya Vélez LP, Mejía Motta IE. Heroin use and injection risk behaviors in Colombia: implications for HIV/AIDS prevention. Subst Use Misuse. 2016;51:230–40.CrossRefPubMedPubMedCentral
40.
go back to reference Castaño Pérez GA, Calderón Vallejo GA. Patterns of heroin use in a sample of consumers in Medellín-Colombia. Rev Bras Epidemiol. 2012;15:504–22.CrossRefPubMed Castaño Pérez GA, Calderón Vallejo GA. Patterns of heroin use in a sample of consumers in Medellín-Colombia. Rev Bras Epidemiol. 2012;15:504–22.CrossRefPubMed
44.
go back to reference Siegel JE, Weinstein MC, Fineberg HV. Bleach programs for preventing AIDS among iv drug users: modeling the impact of HIV prevalence. Am J Public Health. 1991;81:1273–9.CrossRefPubMedPubMedCentral Siegel JE, Weinstein MC, Fineberg HV. Bleach programs for preventing AIDS among iv drug users: modeling the impact of HIV prevalence. Am J Public Health. 1991;81:1273–9.CrossRefPubMedPubMedCentral
45.
go back to reference Rhodes T. Risk environments and drug harms: a social science for harm reduction approach. Int J Drug Policy. 2009;20:193–201.CrossRefPubMed Rhodes T. Risk environments and drug harms: a social science for harm reduction approach. Int J Drug Policy. 2009;20:193–201.CrossRefPubMed
Metadata
Title
Young Drug Users: a Vulnerable Population and an Underutilized Resource in HIV/HCV Prevention
Authors
Pedro Mateu-Gelabert
H. Guarino
K. Quinn
P. Meylakhs
S. Campos
A. Meylakhs
D. Berbesi
D. Toro-Tobón
E. Goodbody
D.C. Ompad
S. R. Friedman
Publication date
01-08-2018
Publisher
Springer US
Published in
Current HIV/AIDS Reports / Issue 4/2018
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-018-0406-z

Other articles of this Issue 4/2018

Current HIV/AIDS Reports 4/2018 Go to the issue

HIV and Technology (J Simoni and K Horvath, Section Editors)

eHealth to Enhance Treatment Adherence Among Youth Living with HIV

The Global Epidemic (SH Vermund, Section Editor)

Federal Response to the Opioid Crisis

HIV and Technology (J Simoni and K Horvath, Section Editors)

eHealth and Prevention of Mother-to-Child Transmission of HIV

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine